3rdPartyFeeds

Tilray Brands Reports Third Quarter Fiscal Year 2023 Financial Results and Announces Accretive Acquisition of 100% of HEXO Corp.

Delivered $145.6 Million in Net Revenue and 16th Consecutive Quarter of Positive Adjusted EBITDA Maintained #1 Cannabis Market Share Position in Canada, the Largest Federally Legal Cannabis Market in the World; With HEXO Transaction, Poised to Substantially Increase Canadian Revenue Medical Cannabis Leader in Europe Achieved Key Efficiency Milestones on Accelerated Path to Positive Cash Flow, Company Reiterates Cash Flow Guidance LEAMINGTON, Ontario and NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) Read More...
Tilray Brands, Inc.

Tilray Brands, Inc.

Delivered $145.6 Million in Net Revenue and 16thConsecutive Quarter of Positive Adjusted EBITDA

Maintained #1 Cannabis Market Share Position in Canada, the Largest Federally Legal Cannabis Market in the World; With HEXO Transaction, Poised to Substantially Increase Canadian Revenue

Medical Cannabis Leader in Europe

Achieved Key Efficiency Milestones on Accelerated Path to Positive Cash Flow, Company Reiterates Cash Flow Guidance

LEAMINGTON, Ontario and NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) —  Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported financial results for the third fiscal quarter ended February 28, 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Tilray also announces today that it entered into a definitive agreement to acquire HEXO Corp. (NASDAQ: HEXO; TSX: HEXO) for an aggregate purchase price of approximately US$56 million, to be satisfied through the issuance of 0.4352 of Tilray Common Stock for each outstanding HEXO share. The acquisition, which is structured as an arrangement under applicable Canadian laws (the “Arrangement”), builds on the successful strategic alliance between the two companies and positions Tilray for continued strong growth and market leadership in Canada, the largest federally legal cannabis market in the world.

The completion of the Arrangement is subject to customary and negotiated closing conditions, including HEXO shareholder approval and court approval, and is expected to close in June 2023. Further information about the HEXO transaction is included in an investor presentation available on the investor section of Tilray.com and in our Current Report on Form 8-K filed today.

Financial Highlights

  • Net revenue increased to $145.6 million compared to $144.1 million in the prior quarter. On a constant currency basis, net revenue was $154.2 million in the third quarter of 2023, up 2% from the prior year quarter.

  • Distribution revenue increased 5% to $65.4 million, from the prior year quarter. On a constant currency basis, distribution revenue increased 12% to $70.1 million.

  • Gross Profit (Loss) was ($11.7) million, while adjusted gross profit was $44.3 million. Gross margin was negative 8%, while adjusted gross margin rose to 30% from 26% in the year-ago quarter.

  • Adjusted cannabis gross profit increased to $22.2 million from $18.0 million in the prior year quarter, while adjusted gross margin percentage increased to 47% from 33%.

  • Achieved $22 million in annualized run-rate savings (and $12 million in actual cost savings) as part of $30 million cost optimization plan announced in Q4 of 2022; total annualized cash cost-savings since the closing of the Tilray-Aphria transaction reached $122 million.

  • Adjusted EBITDA of $14.0 million, marking 16th consecutive quarter of positive adjusted EBITDA. Currently expecting Adjusted EBITDA in the range of $60 to $66 million, a greater than 30% increase from the prior year.

  • Strong financial position with $408.3 million in cash and marketable securities.

  • Reiterated expectation to deliver positive free cash flow from operating segments in fiscal 2023.

  • Recorded non-cash $1.1 billion net asset reduction resulting from higher interest rates and a decline in market capitalization. This non-cash net asset reduction has no impact on the Company’s compliance with debt covenants, its cash flows or available liquidity.

Irwin D. Simon, Tilray Brands’ Chairman and Chief Executive Officer, stated, “During the quarter, we continued to focus on our highest priorities: sustaining and growing the top-line across core markets and geographies while optimizing the platform to achieve positive free cash flow on an accelerated timeline. We are executing on both fronts and delivered revenue growth despite challenging market dynamics across Canada, Europe, and the U.S, as well as our 16th consecutive quarter of positive adjusted EBITDA.”

Mr. Simon continued, “Looking ahead, we are focused on being the leading, most diversified cannabis lifestyle and CPG company in the world. Our strategy to deliver on this vision is centered on pursuing targeted growth opportunities, as reflected in our opportunistic acquisitions of both Montauk Brewing Company and HEXO, which has made significant strides in driving operating efficiency and improving profitability while continuing to invest in industry-leading brands. We are incredibly excited about our combined prospects moving forward with HEXO and expect a seamless integration of HEXO’s business into our efficient, built-to-last platform. At the same time, we will continue our relentless focus on cost and operational efficiencies and strengthening our industry-leading balance sheet to deliver sustained, profitable growth and shareholder value.”

Mark Attanasio, Chairman of HEXO, said, “Over the past year, HEXO established and has been executing on a rigorous cost-cutting and balance sheet optimization plan.  As we began working with Tilray last year, the value that could be achieved through the combination of our businesses in order to compete and drive profitable growth in the highly fragmented Canadian market was immediately clear. With the recent headwinds in the cannabis industry, our Board determined that HEXO shareholders would benefit from being part of Tilray’s diversified business and from the strong plan in place they have to reinforce their industry leadership, continue to strengthen the top and bottom lines, and to drive value creation. With Irwin and his leadership team, we are confident that our brands will continue to grow and thrive as part of Tilray Brands.”

Operating Highlights

Leadership in Global Cannabis Operations, Brands, and Market Share:

  • In Canada, despite ongoing challenging cannabis market conditions, quarter over quarter, Tilray maintained its #1 cannabis market share position. With the addition of HEXO’s leading high-growth brands, the Company expects to significantly bolster its position supported by low-cost operations and complimentary distribution across all Canadian geographies. The combined company is expected to strengthen Tilray’s existing Canadian position with 12.9% pro-forma market share and #1 market position across all major markets and a leading share across most product categories. This includes anticipated pro-forma net sales of approximately US$215M and the leading low-cost operations with distribution across all Canadian geographies.

  • Capitalizing on the unrivaled platform provided by its cultivation and distribution operations across Portugal and Germany and the leadership team’s depth of commercial and regulatory expertise, Tilray is focused on growing its leading market share in medical cannabis in the countries in which it distributes today and achieving early-mover advantage in new countries as cannabis legalization continues to proliferate across Europe.

Maximizing the High-Growth Potential of U.S. CPG and Craft-Beverage Portfolio:

  • In the third quarter, Tilray made substantial strides across its five craft-beverage brands including leaders SweetWater Brewing Company, Breckenridge Distillery, and Montauk Brewing Company, and its wellness brand Manitoba Harvest. By expanding recognition and distribution, Tilray will be well positioned to immediately leverage these brands to drive significant additional revenue in adult-use cannabis, pending federal legalization.

Strategic Growth Actions

  • April 2023 – Tilray Medical Expands Footprint in Europe and Broadens Distribution Across the Czech Republic

  • April 2023 – SweetWater Brewing Company Expands Across 44 States with Nevada Launch

  • April 2023 – Manitoba Harvest Expands Whole Foods Market Distribution

  • April 2023 – Breckenridge Distillery Wins Big at Whisky Magazine’s 2023 World Whiskies Awards

  • March 2023 – Alpine Beer Opens Taproom at Petco Park Stadium in San Diego

  • March 2023 – Breckenridge Distillery Establishes March 31st as National Après Day

  • March 2023 – Montauk Brewing Expands Distribution Across the Northeast

  • March 2023 – Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan

  • March 2023 – SweetWater Brewing Company Brings Back Popular Triple Tail Tropical India Pale Ale

  • March 2023 – SweetWater Brewing Company Introduces New West Coast Style India Pale Ale

  • March 2023 – Potently Canadian Cannabis Brand, CANACA, Introduces New Collection of Terpene Rich Products Across Canada

  • February 2023 – Good Supply Cannabis Brand Launches Canada’s Strongest Infused Pre-Rolls

  • February 2023 – Breckenridge Distillery Strikes Gold at 2023 World Whiskies Awards

  • February 2023 – Good Supply Cannabis Brand Launches New Product Lineup

  • February 2023 – SweetWater Announces 420 Fest 2023 Lineup and Venue

  • February 2023 – Breckenridge Distillery Launches Limited-Edition Sexy Motor Oil Whiskey for Valentine’s Day

  • February 2023 – SweetWater Brewing Company Introduces New Crisp Lager to Year-Round Lineup

  • January 2023 – Alpine Beer Launches INFINITE HAZE Hazy IPA

  • January 2023 – Solei Cannabis Brand Introduces New Approach to Wellness with New Product Lineup and Brand Refresh

  • January 2023 – SweetWater Brewing Company Celebrates 26 Years of Brewing with Throwback Beers, Jam Bands

Live Conference Call and Audio Webcast
Tilray Brands will host a webcast to discuss these results today at 5:00 p.m. ET. Investors may join the live webcast available on the Investors section of the Company’s website at www.tilray.com. The webcast will also be archived after the call concludes.

About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Patients and consumers trust Tilray Brands to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality and beloved brands that address the needs of the consumers, customers and patients we serve. A pioneer in cannabis research, cultivation, and distribution, Tilray Brands’ unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on Tilray Brands, visit www.Tilray.com and follow @Tilray

Cautionary Statement Concerning Forward-Looking Statements

Certain statements in this press release constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.

Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become the world’s leading cannabis-focused consumer branded company; the Company’s ability to generate its targeted amount of Adjusted EBITDA for the fiscal year ending May 31, 2023; the Company’s expectation to be free-cash flow positive in its operating business units; the Company’s ability to achieve long term profitability; the Company’s ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company’s ability to successfully complete the acquisition of HEXO; the Company’s ability to successfully achieve revenue growth, production and supply chain efficiencies, synergies and cost savings, including with respect to the HEXO acquisition; expansion of medical and recreational sales legalization across the global cannabis industry, including in Europe; and the Company’s anticipated investments and acquisitions, including in organic and strategic growth, partnership efforts, product offerings and other initiatives.

Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Use of Non-U.S. GAAP Financial Measures
This press release and the accompanying tables include non-GAAP financial measures, including adjusted gross margin, Adjusted gross profit, Adjusted EBITDA, Adjusted net income and free cash flow. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company’s operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company’s Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.

Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, impairments, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company’s GAAP financial results.

The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company’s consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year.

Adjusted EBITDA is calculated as net income (loss) before income tax expense (recovery); interest expense, net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; impairments; purchase price accounting step-up; facility start-up and closure costs; lease expense; litigation (recovery) costs; restructuring costs; and transaction (income) costs. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Adjusted gross profit, is calculated as gross profit adjusted to exclude the impact of inventory valuation adjustment and purchase price accounting valuation step-up. A reconciliation of Adjusted gross profit, excluding inventory valuation adjustments and purchase price accounting valuation step-up, to gross profit, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Adjusted gross margin, excluding inventory valuation adjustments and purchase price accounting valuation step-up, is calculated as revenue less cost of sales adjusted to add back inventory valuation adjustments and amortization of inventory step-up, divided by revenue. A reconciliation of Adjusted gross margin, excluding inventory valuation adjustments and purchase price accounting valuation step-up, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Adjusted net income is calculated as net (loss) income plus (minus) non-operating income (expense), net, change in fair value of contingent consideration, impairments; inventory write down, litigation (recovery) costs, restructuring costs, and transaction (income) costs. A reconciliation of Adjusted net income, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Free cash flow is comprised of two GAAP measures deducted from each other which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.

For further information:

Media: Berrin Noorata, [email protected]
Investors: Raphael Gross, +1-203-682-8253, [email protected]

Consolidated Statements of Financial Position

February 28,

May 31,

(in thousands of US dollars)

2023

2022

Assets

Current assets

Cash and cash equivalents

$

164,997

$

415,909

Marketable Securities

243,286

Accounts receivable, net

78,342

95,279

Inventory

202,800

245,529

Prepaids and other current assets

69,087

46,786

Total current assets

758,512

803,503

Capital assets

425,263

587,499

Right-of-use assets

6,492

12,996

Intangible assets

994,325

1,277,875

Goodwill

2,005,701

2,641,305

Interest in equity investees

4,638

4,952

Long-term investments

7,620

10,050

Convertible notes receivable

168,356

111,200

Other assets

4,993

314

Total assets

$

4,375,900

$

5,449,694

Liabilities

Current liabilities

Bank indebtedness

$

18,125

$

18,123

Accounts payable and accrued liabilities

163,422

157,431

Contingent consideration

16,219

16,007

Warrant liability

7,414

14,255

Current portion of lease liabilities

2,528

6,703

Current portion of long-term debt

77,892

67,823

Current portion of convertible debentures payable

184,082

Total current liabilities

469,682

280,342

Long – term liabilities

Lease liabilities

8,598

11,329

Long-term debt

89,419

117,879

Convertible debentures payable

223,087

401,949

Deferred tax liabilities

164,412

196,638

Other liabilities

3,335

191

Total liabilities

969,129

1,008,328

Commitments and contingencies (refer to Note 17)

Stockholders’ equity

Common stock ($0.0001 par value; 980,000,000 shares authorized; 617,857,031 and 532,674,887 shares issued and outstanding, respectively)

62

53

Series A Preferred Stock ($0.0001 par value; 10,000,000 shares authorized; 120,000 and nil shares issued and outstanding, respectively)

Additional paid-in capital

5,723,342

5,382,367

Accumulated other comprehensive loss

(42,948

)

(20,764

)

Accumulated Deficit

(2,276,794

)

(962,851

)

Total Tilray Brands, Inc. stockholders’ equity

3,403,662

4,398,805

Non-controlling interests

3,109

42,561

Total stockholders’ equity

3,406,771

4,441,366

Total liabilities and stockholders’ equity

$

4,375,900

$

5,449,694

Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)

For the three months

For the nine months

ended February 28,

Change

% Change

ended February 28,

Change

% Change

(in thousands of U.S. dollars, except for per share data)

2023

2022

2023 vs. 2022

2023

2022

2023 vs. 2022

Net revenue

$

145,589

$

151,871

$

(6,282

)

(4

)%

$

442,936

$

475,047

$

(32,111

)

(7

)%

Cost of goods sold

157,288

112,042

45,246

40

%

363,139

351,497

11,642

3

%

Gross profit (loss)

(11,699

)

39,829

(51,528

)

(129

)%

79,797

123,550

(43,753

)

(35

)%

Operating expenses:

General and administrative

38,999

38,445

554

1

%

117,385

121,401

(4,016

)

(3

)%

Selling

6,452

8,641

(2,189

)

(25

)%

25,792

25,283

509

2

%

Amortization

23,518

24,590

(1,072

)

(4

)%

71,872

84,345

(12,473

)

(15

)%

Marketing and promotion

7,354

7,578

(224

)

(3

)%

23,137

20,163

2,974

15

%

Research and development

171

164

7

4

%

502

1,464

(962

)

(66

)%

Change in fair value of contingent consideration

352

(30,747

)

31,099

(101

)%

563

(29,065

)

29,628

(102

)%

Impairments

1,115,376

1,115,376

NM

1,115,376

1,115,376

NM

Litigation (recovery) costs

(5,230

)

4,215

(9,445

)

(224

)%

(1,970

)

6,489

(8,459

)

(130

)%

Restructuring costs

2,663

2,663

0

%

10,727

795

9,932

1249

%

Transaction (income) costs

5,382

5,023

359

7

%

(3,882

)

35,653

(39,535

)

(111

)%

Total operating expenses

1,195,037

57,909

1,137,128

1964

%

1,359,502

266,528

1,092,974

410

%

Operating loss

(1,206,736

)

(18,080

)

(1,188,656

)

6574

%

(1,279,705

)

(142,978

)

(1,136,727

)

795

%

Interest expense, net

(1,040

)

(2,312

)

1,272

(55

)%

(8,560

)

(22,422

)

13,862

(62

)%

Non-operating income (expense), net

1,213

71,037

(69,824

)

(98

)%

(50,229

)

186,329

(236,558

)

(127

)%

(Loss) income before income taxes

(1,206,563

)

50,645

(1,257,208

)

(2,482

)%

(1,338,494

)

20,929

(1,359,423

)

(6,495

)%

Income taxes (benefit) expense

(10,811

)

(1,830

)

(8,981

)

491

%

(15,313

)

(2,739

)

(12,574

)

459

%

Net (loss) income

$

(1,195,752

)

$

52,475

$

(1,248,227

)

(2,379

)%

(1,323,181

)

23,668

(1,346,849

)

(5,691

)%

Net loss per share – basic and diluted

$

(1.90

)

$

0.09

$

(1.99

)

(2,214

)%

$

(2.20

)

$

0.00

$

(2.20

)

(77,239

)%

Condensed Consolidated Statements of Cash Flows

For the nine months

ended February 28,

Change

% Change

(in thousands of US dollars)

2023

2022

2023 vs. 2022

Cash used in operating activities:

Net (loss) income

$

(1,323,181

)

$

23,668

$

(1,346,849

)

(5691

)%

Adjustments for:

Deferred income tax recovery

(29,537

)

(17,296

)

(12,241

)

71

%

Unrealized foreign exchange loss

13,711

1,699

12,012

707

%

Amortization

101,156

113,824

(12,668

)

(11

)%

Loss (gain) on sale of capital assets

(2

)

(631

)

629

(100

)%

Inventory valuation write down

55,000

12,000

43,000

358

%

Impairments

1,115,376

1,115,376

0

%

Other non-cash items

12,933

962

11,971

1244

%

Stock-based compensation

29,766

27,025

2,741

10

%

Loss (gain) on long-term investments & equity investments

2,843

(2,401

)

5,244

(218

)%

Loss (gain) on derivative instruments

13,534

(210,653

)

224,187

(106

)%

Change in fair value of contingent consideration

563

(29,065

)

29,628

(102

)%

Change in non-cash working capital:

Accounts receivable

18,053

(458

)

18,511

(4042

)%

Prepaids and other current assets

(32,680

)

(953

)

(31,727

)

3329

%

Inventory

(11,808

)

(16,512

)

4,704

(28

)%

Accounts payable and accrued liabilities

(1,419

)

(57,947

)

56,528

(98

)%

Net cash used in operating activities

(35,692

)

(156,738

)

121,046

(77

)%

Cash used in investing activities:

Investment in capital and intangible assets

(8,394

)

(28,470

)

20,076

(71

)%

Proceeds from disposal of capital and intangible assets

2,175

11,526

(9,351

)

(81

)%

Purchase of marketable securities, net

(243,186

)

(243,186

)

0

%

Net cash paid for business acquisition

(28,122

)

326

(28,448

)

(8726

)%

Net cash used in investing activities

(277,527

)

(16,618

)

(260,909

)

1570

%

Cash provided by (used in) financing activities:

Share capital issued, net of cash issuance costs

129,593

129,593

0

%

Shares effectively repurchased for employee withholding tax

(1,189

)

(3,149

)

1,960

(62

)%

Proceeds from long-term debt

1,288

1,288

0

%

Repayment of long-term debt and convertible debt

(64,658

)

(34,570

)

(30,088

)

87

%

Repayment of lease liabilities

(1,114

)

(4,672

)

3,558

(76

)%

Net increase in bank indebtedness

2

8,779

(8,777

)

(100

)%

Net cash provided by (used in) financing activities

63,922

(33,612

)

97,534

(290

)%

Effect of foreign exchange on cash and cash equivalents

(1,615

)

(2,284

)

669

(29

)%

Net decrease in cash and cash equivalents

(250,912

)

(209,252

)

(41,660

)

20

%

Cash and cash equivalents, beginning of period

415,909

488,466

(72,557

)

(15

)%

Cash and cash equivalents, end of period

$

164,997

$

279,214

$

(114,217

)

(41

)%

Other Financial Information: Key Operating Metrics

For the three months

For the nine months

ended February 28,

ended February 28,

(in thousands of U.S. dollars)

2023

2022

2023

2022

Net cannabis revenue

$

47,549

$

55,045

$

156,017

$

184,269

Distribution revenue

65,385

62,532

186,158

198,587

Net beverage alcohol revenue

20,640

19,597

62,689

48,765

Wellness revenue

12,015

14,697

38,072

43,426

Cannabis costs

77,604

37,042

137,800

122,492

Beverage alcohol costs

10,663

8,091

32,932

20,674

Distribution costs

57,964

57,566

165,443

178,093

Wellness costs

8,299

9,343

26,964

30,238

Adjusted gross profit (excluding PPA step-up and inventory valuation adjustments) (1)

44,310

39,829

138,020

135,550

Cannabis adjusted gross margin (excluding inventory valuation adjustments) (1)

47

%

33

%

47

%

40

%

Beverage alcohol adjusted gross margin (excluding PPA step-up) (1)

53

%

59

%

53

%

58

%

Distribution gross margin

11

%

8

%

11

%

10

%

Wellness gross margin

31

%

36

%

29

%

30

%

Adjusted EBITDA (1)

14,015

10,086

39,254

36,543

Cash and cash equivalents and marketable securities

408,283

279,214

408,283

279,214

Working capital

288,830

413,358

288,830

413,358

Net Revenue by Operating Segment

For the three months

% of Total Revenue

For the three months

% of Total Revenue

For the nine months

% of Total Revenue

For the nine months

% of Total Revenue

(In thousands of U.S. dollars)

February 28, 2023

February 28, 2022

February 28, 2023

February 28, 2022

Cannabis business

$

47,549

33%

$

55,045

36%

$

156,017

35%

$

184,269

39%

Distribution business

65,385

45%

62,532

41%

186,158

42%

198,587

42%

Beverage alcohol business

20,640

14%

19,597

13%

62,689

14%

48,765

10%

Wellness business

12,015

8%

14,697

10%

38,072

9%

43,426

9%

Total net revenue

$

145,589

100%

$

151,871

100%

$

442,936

100%

$

475,047

100%

Net Revenue by Operating Segment in Constant Currency

For the three months

For the three months

For the nine months

For the nine months

February 28, 2023

February 28, 2022

February 28, 2023

February 28, 2022

(In thousands of U.S. dollars)

as reported in constant currency

% of Total Revenue

as reported in constant currency

% of Total Revenue

as reported in constant currency

% of Total Revenue

as reported in constant currency

% of Total Revenue

Cannabis business

$

51,007

33%

$

55,045

36%

$

164,746

34%

$

184,269

39%

Distribution business

70,144

45%

62,532

41%

211,676

44%

198,587

42%

Beverage alcohol business

20,640

14%

19,597

13%

62,689

13%

48,765

10%

Wellness business

12,385

8%

14,697

10%

39,144

8%

43,426

9%

Total net revenue

$

154,176

100%

$

151,871

100%

$

478,255

99%

$

475,047

100%

Net Cannabis Revenue by Market Channel

For the three months

% of Total Revenue

For the three months

% of Total Revenue

For the nine months

% of Total Revenue

For the nine months

% of Total Revenue

(In thousands of U.S. dollars)

February 28, 2023

February 28, 2022

February 28, 2023

February 28, 2022

Revenue from Canadian medical cannabis products

$

6,035

13%

$

7,050

13%

$

18,920

12%

$

23,353

13%

Revenue from Canadian adult-use cannabis products

45,318

96%

43,504

79%

156,063

100%

162,632

87%

Revenue from wholesale cannabis products

58

0%

2,804

5%

686

0%

6,763

4%

Revenue from international cannabis products

9,707

20%

15,820

29%

27,834

18%

39,792

22%

Less excise taxes

(13,569

)

-29%

(14,133

)

-26%

(47,486

)

-30%

(48,271

)

-26%

Total

$

47,549

100%

$

55,045

100%

$

156,017

100%

$

184,269

100%

Net Cannabis Revenue by Market Channel in Constant Currency

For the three months

For the three months

For the nine months

For the nine months

February 28, 2023

February 28, 2022

February 28, 2023

February 28, 2022

(In thousands of U.S. dollars)

as reported in constant currency

% of Total Revenue

as reported in constant currency

% of Total Revenue

as reported in constant currency

% of Total Revenue

as reported in constant currency

% of Total Revenue

Revenue from Canadian medical cannabis products

$

6,442

13%

$

7,050

13%

$

20,093

12%

$

23,353

13%

Revenue from Canadian adult-use cannabis products

48,721

96%

43,504

79%

162,777

99%

162,632

87%

Revenue from wholesale cannabis products

62

0%

2,804

5%

726

0%

6,763

4%

Revenue from international cannabis products

10,269

20%

15,820

29%

31,627

19%

39,792

22%

Less excise taxes

(14,487

)

-28%

(14,133

)

-26%

(50,477

)

-31%

(48,271

)

-26%

Total

$

51,007

100%

$

55,045

100%

$

164,746

100%

$

184,269

100%

Other Financial Information: Gross Margin and Adjusted Gross Margin

For the three months ended February 28, 2023

(In thousands of U.S. dollars)

Cannabis

Beverage

Distribution

Wellness

Total

Net revenue

$

47,549

$

20,640

$

65,385

$

12,015

$

145,589

Cost of goods sold

80,362

10,663

57,964

8,299

157,288

Gross profit

(32,813

)

9,977

7,421

3,716

(11,699

)

Gross margin

-69%

48%

11%

31%

-8%

Adjustments:

Inventory valuation adjustments

55,000

55,000

Purchase price accounting step-up

1,009

1,009

Adjusted gross profit

22,187

10,986

7,421

3,716

44,310

Adjusted gross margin

47%

53%

11%

31%

30%

For the three months ended February 28, 2022

(In thousands of U.S. dollars)

Cannabis

Beverage

Distribution

Wellness

Total

Net revenue

$

55,045

$

19,597

$

62,532

$

14,697

$

151,871

Cost of goods sold

37,042

8,091

57,566

9,343

112,042

Gross profit

18,003

11,506

4,966

5,354

39,829

Gross margin

33%

59%

8%

36%

26%

For the nine months ended February 28, 2023

(In thousands of U.S. dollars)

Cannabis

Beverage

Distribution

Wellness

Total

Net revenue

$

156,017

$

62,689

$

186,158

$

38,072

$

442,936

Cost of goods sold

137,800

32,932

165,443

26,964

363,139

Gross profit

18,217

29,757

20,715

11,108

79,797

Gross margin

12%

47%

11%

29%

18%

Adjustments:

Inventory valuation adjustments

55,000

55,000

Purchase price accounting step-up

3,223

3,223

Adjusted gross profit

73,217

32,980

20,715

11,108

138,020

Adjusted gross margin

47%

53%

11%

29%

31%

For the nine months ended February 28, 2022

(In thousands of U.S. dollars)

Cannabis

Beverage

Distribution

Wellness

Total

Net revenue

$

184,269

$

48,765

$

198,587

$

43,426

$

475,047

Cost of goods sold

122,492

20,674

178,093

30,238

351,497

Gross profit

61,777

28,091

20,494

13,188

123,550

Gross margin

34%

58%

10%

30%

26%

Adjustments:

Inventory valuation adjustments

12,000

12,000

Adjusted gross profit

73,777

28,091

20,494

13,188

135,550

Adjusted gross margin

40%

58%

10%

30%

29%

Other Financial Information: Adjusted Earnings Before Interest, Taxes and Amortization

For the three months

For the nine months

ended February 28,

Change

% Change

ended February 28,

Change

% Change

(In thousands of U.S. dollars)

2023

2022

2023 vs. 2022

2023

2022

2023 vs. 2022

Net (loss) income

$

(1,195,752

)

$

52,475

$

(1,248,227

)

(2,379

)%

$

(1,323,181

)

$

23,668

$

(1,346,849

)

(5,691

)%

Income taxes (benefit) expense

(10,811

)

(1,830

)

(8,981

)

491

%

(15,313

)

(2,739

)

(12,574

)

459

%

Interest expense, net

1,040

2,312

(1,272

)

(55

)%

8,560

22,422

(13,862

)

(62

)%

Non-operating income (expense), net

(1,213

)

(71,037

)

69,824

(98

)%

50,229

(186,329

)

236,558

(127

)%

Amortization

33,769

37,020

(3,251

)

(9

)%

101,156

113,824

(12,668

)

(11

)%

Stock-based compensation

9,630

9,355

275

3

%

29,766

27,025

2,741

10

%

Change in fair value of contingent consideration

352

(30,747

)

31,099

(101

)%

563

(29,065

)

29,628

(102

)%

Impairments

1,115,376

1,115,376

NM

1,115,376

1,115,376

NM

Purchase price accounting step-up

1,009

1,009

NM

3,223

3,223

NM

Facility start-up and closure costs

2,100

2,500

(400

)

(16

)%

6,900

10,400

(3,500

)

(34

)%

Lease expense

700

800

(100

)

(13

)%

2,100

2,400

(300

)

(13

)%

Litigation (recovery) costs

(5,230

)

4,215

(9,445

)

(224

)%

(1,970

)

6,489

(8,459

)

(130

)%

Restructuring costs

2,663

2,663

NM

10,727

795

9,932

1249

%

Transaction (income) costs

5,382

5,023

359

7

%

(3,882

)

35,653

(39,535

)

(111

)%

Adjusted EBITDA

$

14,015

$

10,086

$

3,929

39

%

$

39,254

$

36,543

$

2,711

7

%

Other Financial Information: Adjusted Net Loss

For the three months

For the nine months

ended February 28,

Change

% Change

ended February 28,

Change

% Change

(In thousands of U.S. dollars)

2023

2022

2023 vs. 2022

2023

2022

2023 vs. 2022

Net (loss) income

$

(1,195,752

)

$

52,475

$

(1,248,227

)

(2,379

)%

$

(1,323,181

)

$

23,668

$

(1,346,849

)

(5,691

)%

Non-operating income (expense), net

(1,213

)

(71,037

)

69,824

(98

)%

50,229

(186,329

)

236,558

(127

)%

Change in fair value of contingent consideration

352

(30,747

)

31,099

(101

)%

563

(29,065

)

29,628

(102

)%

Impairments

1,115,376

1,115,376

NM

1,115,376

1,115,376

NM

Inventory valuation adjustments

55,000

55,000

NM

55,000

12,000

43,000

358

%

Litigation (recovery) costs

(5,230

)

4,215

(9,445

)

(224

)%

(1,970

)

6,489

(8,459

)

(130

)%

Restructuring costs

2,663

2,663

NM

10,727

795

9,932

1249

%

Transaction (income) costs

5,382

5,023

359

7

%

(3,882

)

35,653

(39,535

)

(111

)%

Adjusted net loss

$

(23,422

)

$

(40,071

)

$

16,649

(42

)%

$

(97,138

)

$

(136,789

)

$

39,651

(29

)%

Adjusted net loss per share – basic and diluted

$

(0.04

)

$

(0.08

)

$

0.04

(54

)%

$

(0.16

)

$

(0.29

)

$

0.13

(44

)%

Other Financial Information: Free Cash Flow

For the three months

For the nine months

ended February 28,

Change

% Change

ended February 28,

Change

% Change

(In thousands of U.S. dollars)

2023

2022

2023 vs. 2022

2023

2022

2023 vs. 2022

Net cash used in operating activities

$

(18,632

)

$

(46,390

)

$

27,758

(60

)%

$

(35,692

)

$

(156,738

)

$

121,046

(77

)%

Less: investments in capital and intangible assets, net

(842

)

(1,352

)

510

(38

)%

(6,219

)

(16,944

)

10,725

(63

)%

Free cash flow

$

(19,474

)

$

(47,742

)

$

28,268

(59

)%

$

(41,911

)

$

(173,682

)

$

131,771

(76

)%

Read More